Cargando…

Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer

Colorectal cancer is one of the top causes of cancer and cancer-related deaths worldwide. The prognosis of metastatic colorectal cancer is poor and treatment options are limited. Many patients will run out of treatment options before they become medically unfit for therapy. As such, there is a need...

Descripción completa

Detalles Bibliográficos
Autores principales: Cimino, Sarah K, Eng, Cathy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667584/
https://www.ncbi.nlm.nih.gov/pubmed/33204182
http://dx.doi.org/10.2147/JEP.S259287
_version_ 1783610342947946496
author Cimino, Sarah K
Eng, Cathy
author_facet Cimino, Sarah K
Eng, Cathy
author_sort Cimino, Sarah K
collection PubMed
description Colorectal cancer is one of the top causes of cancer and cancer-related deaths worldwide. The prognosis of metastatic colorectal cancer is poor and treatment options are limited. Many patients will run out of treatment options before they become medically unfit for therapy. As such, there is a need to expand upon the current understanding of disease biology as well as drug resistance mechanisms in order to create new approaches for therapy. In this review article, we will discuss the mechanistic rationale and clinical data for new drugs and therapeutic combinations under development for metastatic colorectal cancer.
format Online
Article
Text
id pubmed-7667584
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76675842020-11-16 Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer Cimino, Sarah K Eng, Cathy J Exp Pharmacol Review Colorectal cancer is one of the top causes of cancer and cancer-related deaths worldwide. The prognosis of metastatic colorectal cancer is poor and treatment options are limited. Many patients will run out of treatment options before they become medically unfit for therapy. As such, there is a need to expand upon the current understanding of disease biology as well as drug resistance mechanisms in order to create new approaches for therapy. In this review article, we will discuss the mechanistic rationale and clinical data for new drugs and therapeutic combinations under development for metastatic colorectal cancer. Dove 2020-11-11 /pmc/articles/PMC7667584/ /pubmed/33204182 http://dx.doi.org/10.2147/JEP.S259287 Text en © 2020 Cimino and Eng. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Cimino, Sarah K
Eng, Cathy
Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
title Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
title_full Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
title_fullStr Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
title_full_unstemmed Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
title_short Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
title_sort up-and-coming experimental drug options for metastatic colorectal cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667584/
https://www.ncbi.nlm.nih.gov/pubmed/33204182
http://dx.doi.org/10.2147/JEP.S259287
work_keys_str_mv AT ciminosarahk upandcomingexperimentaldrugoptionsformetastaticcolorectalcancer
AT engcathy upandcomingexperimentaldrugoptionsformetastaticcolorectalcancer